

## **Executive Officer Notice : Implementation of Renewed Three-Year Generics Initiative Between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association**

**November 30, 2023**

Effective October 1, 2023, following an agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generics Pharmaceutical Association (CGPA) on a renewed three-year pricing initiative for generic drugs, the drug benefit price of a new single source generic product on the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (CDI) will be 75% of the brand reference price at the time of initial listing and will then drop to 55% of the brand reference price after approximately 3 months (i.e., 3 monthly Formulary updates), if the price tier remains single source. Details can be found on the pCPA website: <https://www.pcpacanada.ca/generic-drug-framework>.

In addition, a generic product of a newly genericized molecule to be listed as Off-Formulary Interchangeable (OFI) and funded through the ministry's Exceptional Access Program (EAP) will be subject to the pCPA Tiered Pricing Framework (TPF). A market entry price assessment completed by the pCPA will be required for the listing of such generic drugs on the Formulary/CDI as OFI/EAP, and a separate unit cost confirmation process will be implemented, similar to the current price confirmation process for generic drugs listed as general or limited use benefits on the Formulary. Additional details about this process will be provided to individual manufacturers making a submission for OFI/EAP generic products in the Notice of Drug Submission Status or recommendation letters. Only generic products compliant with the TPF will be eligible for an interchangeable designation and for funding under the EAP.

Additional Information:

Related inquiries should be directed to: [PublicDrugPrgrms.moh@ontario.ca](mailto:PublicDrugPrgrms.moh@ontario.ca).